Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, 3-Part Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE)
Brief Summary: The primary objectives of the study by study part are:

Part A:

To determine the treatment effect of dupilumab compared with placebo in adult and adolescent patients with EoE after 24 weeks of treatment as assessed by histological and clinical measures and to inform/confirm the final sample size determination for Part B.

Part B:

To demonstrate the efficacy of dupilumab treatment compared with placebo in adult and adolescent patients with EoE after 24 weeks of treatment as assessed by histological and clinical measures.

Part C:

To assess the safety and efficacy of dupilumab treatment in adult and adolescent patients with EoE after up to 52 weeks of treatment as assessed by histological and clinical measures.

The secondary objectives of the study are:

* To evaluate the safety, tolerability, and immunogenicity of dupilumab treatment for up to 52 weeks in adult and adolescent patients with EoE
* To explore the relationship between dupilumab concentration and responses in adult and adolescent patients with EoE, using descriptive analyses
* To evaluate the effects of dupilumab on transcriptomic signatures associated with EoE and type 2 inflammation
* To demonstrate the efficacy of dupilumab treatment compared to placebo after 24 weeks and 52 weeks of treatment in adult and adolescent patients with EoE who have previously received swallowed topical corticosteroids


Options:
A: Arm Label: Oral cromolyn; Type: EXPERIMENTAL; Interventions: Drug: oral cromolyn sodium | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: oral cromolyn sodium; Assigned to Arm(s): Oral cromolyn | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Part A: Dupilumab or Placebo; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab, Drug: Placebo | Arm Label: Part B: Dupilumab or Placebo; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab, Drug: Placebo | Arm Label: Part C: Dupilumab; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab | Intervention Type: DRUG; Name: Dupilumab; Assigned to Arm(s): Part A: Dupilumab or Placebo, Part B: Dupilumab or Placebo, Part C: Dupilumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Part A: Dupilumab or Placebo, Part B: Dupilumab or Placebo
C: Arm Label: IV ABT-308 in asthmatics; Type: EXPERIMENTAL; Interventions: Drug: ABT-308, Drug: Placebo | Arm Label: SC ABT-308 in asthmatics; Type: EXPERIMENTAL; Interventions: Drug: ABT-308, Drug: Placebo | Arm Label: IV ABT-308 in healthy volunteers; Type: EXPERIMENTAL; Interventions: Drug: ABT-308, Drug: Placebo | Intervention Type: DRUG; Name: ABT-308; Assigned to Arm(s): IV ABT-308 in asthmatics, IV ABT-308 in healthy volunteers | Intervention Type: DRUG; Name: ABT-308; Assigned to Arm(s): SC ABT-308 in asthmatics | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): IV ABT-308 in asthmatics, IV ABT-308 in healthy volunteers | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): SC ABT-308 in asthmatics
D: Arm Label: Low dose budesonide tablet; Type: EXPERIMENTAL; Interventions: Drug: low dose budesonide tablet | Arm Label: High dose budesonide tablet; Type: EXPERIMENTAL; Interventions: Drug: high dose budesonide tablet | Arm Label: High dose budesonide suspension; Type: EXPERIMENTAL; Interventions: Drug: high dose budesonide suspension | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: low dose budesonide tablet; Assigned to Arm(s): Low dose budesonide tablet | Intervention Type: DRUG; Name: high dose budesonide tablet; Assigned to Arm(s): High dose budesonide tablet | Intervention Type: DRUG; Name: high dose budesonide suspension; Assigned to Arm(s): High dose budesonide suspension | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B